HCMedi is an innovative handheld medical device company specializing in inhaled drug delivery systems for respiratory disease control.
AADi Bioscience is a clinical stage biopharmaceutical company developing the a potentially best-in-class mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.
Platelet BioGenesis is a Harvard University spinout that is making human platelets from stem cells.
Homology Medicines (NASDAQ: FIXX) is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
PowerVision is a company developing a fluid-based accommodating intraocular lens (IOL).
Bolt Biotherapeutics is a cancer immunotherapy company.
Fortis Therapeutics is an immuno-oncology biotechnology company developing novel antibody drug conjugate (ADC) therapies for prostate cancer and multiple myeloma.
ReadCoor is a company developing and commercializing fluorescent in situ sequencing (FISSEQ) technology, a new generation sequencing platform enabling high throughput RNA-Seq while preserving sample morphology and providing cellular location and spatial image data.
Bonraybio is a development-stage medical device company based in Taiwan with an initial focus targeting the infertility market.

Privately held companies at the time of Vivo’s initial investment.